Pearce IP BioBlast: w/e 23 October 2020

Significant biosimilar activities this week include:

  • 15 Oct 20: Henlius and Essex announced they have entered into a co-development and exclusive license agreement for HLX04 (proposed bevacizumab biosimilar). Under the agreement, Essex will be granted an exclusive license to develop, manufacture and commercialise HLX04 globally.  Essex will be responsible for 80% of the costs and expenses in relation to the development of HLX04. Henlius is entitled to milestone payments of up to US$43 million, as well as royalties of up to 10% of annual net sales of the product.
     

  • 20 Oct 20: NeuClone announced its proposed ustekinumab biosimilar has successfully met all primary and secondary endpoints in Ph I clinical trials. Noelle Sundstrom, CEO of NeuClone announced that the company plans to enter Ph III trials in 2021.  The product is being jointly developed by NeuClone and the Serum Institute of India.
     

  • 20 Oct 20: Daily News Egypt announced Sandoz Egypt has partnered with the Egyptian Cancer Society to launch a rituximab biosimilar in Egypt. Sameh Elbagoury, Sandoz Country Head for Sandoz Egypt and Libya, announced that the biosimilar could reduce the cost of treating Non-Hodgkin Lymphoma by 40%.
     

  • 20 Oct 20: the American Journal of Managed Care reported a new study indicates Celltrion's rituximab biosimilar CT-P10 could lower costs and expand patient access to biologic therapy for primary Sjogren syndrome.
     

  • 21 Oct 20: Biogen released its Q3 2020 results, reporting a 7% increase in revenue of Benepali® (biosimilar etanercept), 14% increase in revenue of Imraldi® (biosimilar adalimumab), and 49% increase in revenue of Flixabi® (infliximab) compared to the same quarter last year.

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

November 9, 2020

Please reload

Search by tags